MIAMI / Jul 25, 2024 / Business Wire / Ontrak, Inc (NASDAQ: OTRK), a leading AI-powered and technology-enabled behavioral healthcare company, announced the impressive results of a formal evaluation conducted on the Ontrak WholeHealth+ program. The study evaluated the program’s impact on one of its Medicaid health plan customer’s medical costs. The findings are significant and validate the impact of our program to our customers.
Key Findings from the Evaluation:
Final results of the 36-month retrospective observational study have shown statistically significant, difference-in-differences savings of gross all-cause medical costs over 24 months of $721 PMPM (P<0.001) among Ontrak’s treated group of members who graduated the Ontrak WholeHealth+ program compared with matched controls. For the first time, the study went further to evaluate members who did not graduate the Ontrak WholeHealth+ program but were enrolled for a minimum of five months. For this cohort, which averaged an 8.2 month enrollment period, the study shows statistically significant, difference-in-differences savings of gross all-cause medical costs over the enrollment period of $508 PMPM (P<0.05) compared with matched controls. This study provides further evidence of the effectiveness of Ontrak’s WholeHealth+ program in reducing avoidable healthcare expenditures and improving patient outcomes. Ontrak Health has previously measured Medicare and Commercial member difference in difference gross savings of $485 PMPM over 24 months for graduates of its program as part of its independently validated 2021 Treatment Effect Study that was published in the American Journal of Managed Care.
Katie Lord, Vice President of Program Analytics and Outcomes at Ontrak Health, emphasized the significance of these results, stating, “Our latest comprehensive study has once again confirmed the substantial impact of our WholeHealth+ program on healthcare cost reduction. Achieving statistically significant results of $721 PMPM and $508 PMPM for graduates and non-graduates of our program, respectively, is a testament to our commitment to provide evidence-based solutions and data driven insights that our customers need and want.”
This study includes Medicaid members from a prominent existing health plan customer, who are enrolled in Ontrak’s WholeHealth+ program designed around four fundamental capabilities:
Brandon LaVerne, Chief Executive Officer and Chief Operating Officer of Ontrak Health, stated, “Ontrak Health continues to innovate and provide solutions for those most impacted in our society by depression, anxiety and substance use disorder. Our data has shown time and again that unaddressed behavioral health issues, combined with multiple comorbid conditions, increases healthcare costs and inpatient care utilization. Ontrak Health’s WholeHealth+ solution has been proven to significantly reduce these costs and unnecessary utilization.”
To learn more about Ontrak Health visit ontrakhealth.com
About Ontrak, Inc.
Ontrak, Inc. is a leading AI and technology-enabled behavioral healthcare company, whose mission is to help improve the health and save the lives of as many people as possible. Ontrak identifies, engages, activates, and provides care pathways to treatment for the most vulnerable members of the behavioral health population who would otherwise fall through the cracks of the healthcare system. We engage individuals with anxiety, depression, substance use disorder and chronic disease through personalized care coaching and customized care pathways that help them receive the treatment and advocacy they need, despite the socio-economic, medical and health system barriers that exacerbate the severity of their comorbid illnesses. The company’s integrated intervention platform uses AI, predictive analytics and digital interfaces combined with dozens of care coach engagements to deliver improved member health, better healthcare system utilization, and durable outcomes and savings to healthcare payors.
Last Trade: | US$1.73 |
Daily Change: | -0.05 -2.81 |
Daily Volume: | 39,790 |
Market Cap: | US$5.540M |
November 13, 2024 November 06, 2024 September 11, 2024 September 05, 2024 August 29, 2024 |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREAstria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB